Scholar Rock Holding Co. (NASDAQ:SRRK) Stock Holdings Lifted by MetLife Investment Management LLC

MetLife Investment Management LLC raised its position in Scholar Rock Holding Co. (NASDAQ:SRRK) by 16.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,667 shares of the company’s stock after purchasing an additional 6,701 shares during the quarter. MetLife Investment Management LLC’s holdings in Scholar Rock were worth $2,017,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. GAMMA Investing LLC grew its stake in Scholar Rock by 51.8% in the fourth quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock valued at $34,000 after purchasing an additional 269 shares in the last quarter. Global Retirement Partners LLC grew its stake in Scholar Rock by 584.7% in the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company’s stock valued at $39,000 after purchasing an additional 766 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in shares of Scholar Rock by 1,321.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company’s stock worth $48,000 after acquiring an additional 1,031 shares in the last quarter. Amalgamated Bank boosted its stake in shares of Scholar Rock by 30.6% during the 4th quarter. Amalgamated Bank now owns 2,643 shares of the company’s stock worth $114,000 after acquiring an additional 620 shares in the last quarter. Finally, KBC Group NV bought a new stake in shares of Scholar Rock during the 4th quarter worth about $131,000. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Analysts Set New Price Targets

Separately, Wedbush reiterated an “outperform” rating and set a $50.00 price target on shares of Scholar Rock in a research note on Tuesday, March 25th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Scholar Rock has an average rating of “Buy” and a consensus target price of $42.67.

Insider Transactions at Scholar Rock

In other news, CFO Edward H. Myles sold 7,809 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $36.83, for a total value of $287,605.47. Following the sale, the chief financial officer now owns 140,740 shares in the company, valued at approximately $5,183,454.20. This trade represents a 5.26 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Katie Peng sold 1,006 shares of the firm’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $34.42, for a total value of $34,626.52. Following the completion of the transaction, the director now directly owns 30,319 shares of the company’s stock, valued at approximately $1,043,579.98. This trade represents a 3.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 250,231 shares of company stock worth $9,056,086. Insiders own 13.30% of the company’s stock.

Scholar Rock Trading Down 3.5 %

Shares of Scholar Rock stock opened at $31.67 on Tuesday. The company’s fifty day simple moving average is $32.64 and its 200-day simple moving average is $35.76. The company has a market cap of $3.00 billion, a price-to-earnings ratio of -13.48 and a beta of 0.56. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. Scholar Rock Holding Co. has a 1 year low of $6.76 and a 1 year high of $46.98.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.